Blockbuster drugs

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising.

BeiGene still bleeding red ink despite blockbuster drug

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
BGNE.US 6160.HK 688235.SHG

Recent Articles

RELATED ARTICLES

  1. BeiGene
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
  2. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  3. Cancer drug maker Genfleet joins Hong Kong IPO influx
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  6. Cancer drug maker Biostar shines on Hong Kong market debut
    2563.HK
  7. Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva